Patents by Inventor Jonathan Shannon

Jonathan Shannon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11926600
    Abstract: The present invention relates to sulfonylureas and sulfonylthioureas comprising a monocyclic imidazolyl group of formula (I): wherein Q is selected from O or S, R1 is an imidazolyl group, wherein the imidazolyl group is unsubstituted or substituted with one or more monovalent substituents, and R2 is a cyclic group substituted at the ?-position, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.
    Type: Grant
    Filed: August 15, 2018
    Date of Patent: March 12, 2024
    Assignee: INFLAZOME LIMITED
    Inventors: Matthew Cooper, David Miller, Angus MacLeod, Stephen Thom, Stephen St-Gallay, Jonathan Shannon
  • Patent number: 11905252
    Abstract: The present invention relates to sulfonylureas and sulfonylthioureas of formula (I) comprising a 5-membered heteroaryl ring attached to the sulfonyl group, wherein the heteroaryl ring is di-substituted at the 3- and 4-positions relative to the point of attachment of the sulfonyl group, and wherein the group attached to the terminal nitrogen atom of the urea group is either a 1,2,3,5,6,7-hexahydro-s-indacen-4-yl group substituted at the 8-position, or a heteroaryl group substituted at the alpha and alpha? positions. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP3 inhibition.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: February 20, 2024
    Assignee: INFLAZOME LIMITED
    Inventors: Matthew Cooper, David Miller, Angus Macleod, Jonathan Shannon
  • Patent number: 11773058
    Abstract: The present invention relates to compounds of formula (I): Formula (I) wherein Q is selected from O or S; L is a saturated or unsaturated, optionally substituted C1-C12 hydrocarbylene group optionally including one or more heteroatoms N, O or S; R1 is —NR3R4, —OR5, —(C?NR6)R7, —(CO)R8, —CN, —N3, a quaternary ammonium group or an optionally substituted heterocycle; R3, R4, R5, R6, R7 and R8 are each independently hydrogen or a saturated or unsaturated, optionally substituted C1-C10 hydrocarbyl group optionally including one or more heteroatoms N, O or S; wherein optionally L and R3, or L and R4, or R3 and R4, or L and R5, or L and R6, or L and R7, or R6 and R7, or L and R8 together with the atom(s) to which they are attached may form a 3- to 12-membered, saturated or unsaturated, optionally substituted cyclic group; and R2 is a cyclic group substituted at the a-position, wherein R2 may optionally be further substituted; provided that the atom of L which is attached to the sulfur atom of the sulfonylurea group
    Type: Grant
    Filed: August 15, 2018
    Date of Patent: October 3, 2023
    Assignee: INFLAZOME LIMITED
    Inventors: David Miller, Angus MacLeod, Jimmy Van Wiltenburg, Stephen Thom, Stephen St-Gallay, Jonathan Shannon
  • Publication number: 20230228723
    Abstract: A gas monitor configured to monitor at least one target gas in an environmental mixture, by separating and concentrating the target gas and then adjusting for the concentration factor. The adjustment may also take into account sensor sensitivities to other gases. Methods for adjustment of target gas results and increasing accuracy of monitoring are described.
    Type: Application
    Filed: February 10, 2021
    Publication date: July 20, 2023
    Inventors: Michael Potas, Gennadiy Volkov, Alex Hatzimihali, Joshua Dunford, Jonathan Shannon, Alex Matthews, Jason Robert Potas
  • Publication number: 20230121952
    Abstract: The present invention relates to macrocyclic compounds, such as macrocyclic sulfonyl triazoles. The present invention further relates to associated salts, solvates, prodrugs and pharmaceutical compositions, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP3 inhibition.
    Type: Application
    Filed: February 16, 2021
    Publication date: April 20, 2023
    Inventors: Matthew COOPER, David MILLER, Angus MACLEOD, Stephen THOM, Jonathan SHANNON, Celia Amparo INCERTI-PRADILLOS, Thomas ALANINE, Shawn JOHNSTONE, Juliette SABBATANI
  • Patent number: 11623922
    Abstract: The present invention relates to compounds of formula (I): wherein Q is selected from O or S; R1 is a saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include cyclic groups, wherein the hydrocarbyl group may optionally be substituted, and wherein the hydrocarbyl group may optionally include one or more heteroatoms N, O or S in its carbon skeleton; and R2 is a cyclic group substituted at the a-position, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.
    Type: Grant
    Filed: October 3, 2018
    Date of Patent: April 11, 2023
    Assignee: INFLAZOME LIMITED
    Inventors: David Miller, Stephen Thom, Stephen St-Gallay, Jonathan Shannon, Paul Leeson
  • Patent number: 11613542
    Abstract: The present invention relates to sulfonylureas and sulfonylthioureas comprising a 5-membered nitrogen-containing heteroaryl ring attached to the sulfonyl group, wherein the heteroaryl ring is substituted with a nitrogen-containing group R1? wherein R1 contains from 1 to 7 atoms other than hydrogen or halogen. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.
    Type: Grant
    Filed: August 15, 2018
    Date of Patent: March 28, 2023
    Assignee: Inflazome Limited
    Inventors: Matthew Cooper, David Miller, Angus Macleod, Stephen Thom, Stephen St-Gallay, Jonathan Shannon, Thomas Alanine, Stuart Onions, Ian Strutt, Jokin Carrillo Arregui
  • Publication number: 20230037255
    Abstract: The present invention relates to compounds of formula (I) wherein Q is selected from O or S; R1 is a non-aromatic heterocyclic group comprising at least one ring nitrogen atom, wherein R1 is attached to the sulfur atom of the sulfonylurea group by a ring carbon atom, and wherein R1 may optionally be substituted; and R2 is a cyclic group substituted at the ?-position, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.
    Type: Application
    Filed: August 16, 2022
    Publication date: February 2, 2023
    Inventors: Matthew COOPER, David MILLER, Angus MACLEOD, Jimmy VAN WILTENBURG, Stephen THOM, Stephen ST-GALLAY, Jonathan SHANNON
  • Patent number: 11542255
    Abstract: The present invention relates to sulfonylureas and sulfonylthioureas comprising a 5-membered heteroaryl ring attached to the sulfonyl group, wherein the heteroaryl ring is di-substituted at the 3- and 4-positions relative to the point of attachment of the sulfonyl group, wherein at least one of the di-substituents contains a nitrogen atom. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.
    Type: Grant
    Filed: August 15, 2018
    Date of Patent: January 3, 2023
    Assignee: INFLAZOME LIMITED
    Inventors: Matthew Cooper, David Miller, Angus MacLeod, Stephen Thom, Stephen St-Gallay, Jonathan Shannon, Thomas Alanine, Stuart Onions, Ian Strutt
  • Publication number: 20220389031
    Abstract: The present invention relates to macrocyclic compounds, such as macrocyclic sulfonyl amides. The present invention further relates to associated salts, solvates, prodrugs and pharmaceutical compositions, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP3 inhibition.
    Type: Application
    Filed: August 13, 2020
    Publication date: December 8, 2022
    Inventors: Matthew COOPER, David MILLER, Angus MACLEOD, Stephen THOM, Jonathan SHANNON, Celia Amparo INCERTI-PRADILLOS, Christopher Gordon MCPHERSON
  • Patent number: 11518739
    Abstract: The present invention relates to compounds of formula (I): wherein Q is selected from O or S; R1 is a saturated or unsaturated, optionally substituted C1-C15 hydrocarbyl group, wherein the atom of R1 which is attached to the sulfur atom of the sulfonylurea group is not a ring atom of a cyclic group; and R2 is a cyclic group substituted at the ?-position, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.
    Type: Grant
    Filed: August 15, 2018
    Date of Patent: December 6, 2022
    Assignee: INFLAZOME LIMITED
    Inventors: David Miller, Angus Macleod, Jimmy Van Wiltenburg, Stephen Thom, Stephen St-Gallay, Jonathan Shannon
  • Patent number: 11465992
    Abstract: The present invention relates to compounds of formula (I): wherein Q is selected from O or S; R1 is a non-aromatic heterocyclic group comprising at least one ring nitrogen atom, wherein R1 is attached to the sulfur atom of the sulfonylurea group by a ring carbon atom, and wherein R1 may optionally be substituted; and R2 is a cyclic group substituted at the ?-position, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.
    Type: Grant
    Filed: July 4, 2018
    Date of Patent: October 11, 2022
    Assignee: INFLAZOME LIMITED
    Inventors: Matthew Cooper, David Miller, Angus MacLeod, Jimmy Van Wiltenburg, Stephen Thom, Stephen St-Gallay, Jonathan Shannon
  • Publication number: 20220289766
    Abstract: The present invention relates to macrocyclic compounds, such as macrocyclic sulfonyl ureas. The present invention further relates to associated salts, solvates, prodrugs and pharmaceutical compositions and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP3 inhibition.
    Type: Application
    Filed: August 13, 2020
    Publication date: September 15, 2022
    Inventors: Matthew COOPER, David MILLER, Angus MACLEOD, Thomas ALANINE, Stephen THOM, Jonathan SHANNON, Jokin CARRILLO ARREGUI, Stephen ST-GALLAY
  • Publication number: 20220289692
    Abstract: The present invention relates to substituted5-membered nitrogen containing heteroaryl compounds, such as triazole esters, where the heteroaryl ring is further substituted via a linking group such as —NH— with a cyclic group which in turn is substituted at the a-position. The present invention further relates to associated salts, solvates, prodrugs and pharmaceutical compositions, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP3 inhibition.
    Type: Application
    Filed: September 4, 2020
    Publication date: September 15, 2022
    Inventors: David MILLER, Angus MACLEOD, Jonathan SHANNON, Jokin CARRILLO ARREGUI, Diana CASTAGNA, Jimmy VAN WILTENBURG, Jacobus Antonius Joseph DEN HARTOG
  • Patent number: 11377443
    Abstract: A compound which is an arylimidazolyl isoxazole of formula (I): (Formula (I)) or a pharmaceutically acceptable salt thereof. The compound has activity in modulating the activity of p300 and/or CBP and is used to treat cancer, particularly prostate cancer.
    Type: Grant
    Filed: May 14, 2020
    Date of Patent: July 5, 2022
    Assignee: CELLCENTRIC LIMITED
    Inventors: Neil Anthony Pegg, Stuart Thomas Onions, David Michel Adrien Taddei, Jonathan Shannon, Silvia Paoletta, Richard James Brown, Don Smyth, Gareth Harbottle
  • Patent number: 11370776
    Abstract: The present invention relates to compounds of formula (I): wherein Q is O or S, R1 is a 6-membered heteroaryl group containing at least one nitrogen atom in the 6-membered ring structure, wherein R1 may optionally be substituted, and R2 is a cyclic group substituted at the ?-position, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.
    Type: Grant
    Filed: July 4, 2018
    Date of Patent: June 28, 2022
    Assignee: INFLAZOME LIMITED
    Inventors: Matthew Cooper, David Miller, Angus Macleod, Jimmy Van Wiltenburg, Stephen Thom, Stephen St-Gallay, Jonathan Shannon
  • Publication number: 20220194923
    Abstract: The present invention relates to compounds of formula (I): wherein Q is selected from O or S; R1 and R3 are each independently hydrogen or an optionally substituted hydrocarbyl group, or R1 and R3 together with the nitrogen atom to which they are attached may form a 3- to 12-membered optionally substituted cyclic group; and R2 is a cyclic group substituted at the position, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.
    Type: Application
    Filed: August 12, 2019
    Publication date: June 23, 2022
    Inventors: Matthew COOPER, David MILLER, Angus MACLEOD, Jonathan SHANNON, Jokin CARRILLO ARREGUI, Jimmy VAN WILTENBURG, Jochem Theodoor VAN HERPT
  • Publication number: 20220106289
    Abstract: The present application relates to compounds with NLRP3inhibitory activity and to associated salts, solvates, prodrugs and pharmaceutical compositions. The present application further relates to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP3inhibition.
    Type: Application
    Filed: November 22, 2019
    Publication date: April 7, 2022
    Inventors: Matthew COOPER, David MILLER, Angus MACLEOD, Jonathan SHANNON, Stephen THOM, Ian STRUTT, Diana CASTAGNA, Jokin CARRILLO ARREGUI, Jimmy VAN WILTENBURG
  • Publication number: 20220106288
    Abstract: The present invention relates to compounds of formula (I): wherein A, B, X, Y, R1, R4 and R7 are as defined in the specification. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.
    Type: Application
    Filed: August 12, 2019
    Publication date: April 7, 2022
    Inventors: Angus MACLEOD, Jonathan SHANNON, Stephen THOM, Jokin CARRILLO ARREGUI, Thomas ALANINE
  • Publication number: 20210347737
    Abstract: The present invention relates to sulfonylureas and sulfonylthioureas of formula (I) comprising a 5-membered heteroaryl ring attached to the sulfonyl group, wherein the heteroaryl ring is di-substituted at the 3- and 4-positions relative to the point of attachment of the sulfonyl group, and wherein the group attached to the terminal nitrogen atom of the urea group is either a 1,2, 3,5,6, 7-hexahydro-s-indacen-4-yl group substituted at the 8-position, or a heteroaryl group substituted at the alpha and alpha? positions. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP3 inhibition.
    Type: Application
    Filed: March 1, 2019
    Publication date: November 11, 2021
    Inventors: Matthew COOPER, David MILLER, Angus MACLEOD, Jonathan SHANNON